Effect of Uric Acid Control on Serum Creatinine

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Metabolic Disorders

Background:

• Hyperuricemia is linked to chronic kidney disease and cardiovascular issues.
• Metabolic syndrome complicates understanding the cause-effect relationship.
• Fear of allopurinol's nephrotoxicity hinders uric acid reduction.

Purpose of the Study:

• To investigate the relationship between achieving serum uric acid (sUa) levels ≤ 6.0 mg/dL and renal function over time.
• To address the clinical concern that allopurinol may be nephrotoxic.
• To evaluate the impact of controlled uric acid levels on kidney health.

Main Methods:

• Retrospective analysis of 348 hyperuricemia patients' medical records from 2015.
• Patients were categorized into two groups after one year: sUa ≤ 6.0 mg/dL and sUa > 6.0 mg/dL.
• Repeated measures model used to assess the association between sUa and serum creatinine, adjusting for covariates.

Main Results:

• A statistically significant difference in mean serum creatinine was observed between the groups (1.39 mg/dL vs. 1.57 mg/dL, p=0.0015).
• The between-group difference in creatinine was 0.18 mg/dL.
• This difference approaches clinical significance, defined as a 0.2 mg/dL change in serum creatinine.

Conclusions:

• Achieving sUa levels ≤ 6.0 mg/dL is associated with better renal function compared to higher levels.
• The observed creatinine difference of 0.18 mg/dL suggests a potential clinical benefit in managing hyperuricemia.
• Further long-term studies are warranted to confirm the clinical significance of these findings in preventing renal function decline.